Announcements Trials
Browse Landscape

Phase

Phase 3 20Phase 2 9Phase 4 3Phase 1 2

Status

Withdrawn 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 3INDUSTRY 3

Study Type

Interventional 3

Sponsor

Conditions

Giant Cell Tumor of Bone 2Bone Diseases 1

Interventions

Zoledronic Acid 23Bevacizumab 13nilotinib 12Docetaxel 12Paclitaxel 11Everolimus 11Letrozole 10Imatinib Mesylate 10Capecitabine 10Erlotinib Hydrochloride 9Drug Therapy 9Carboplatin 9pegfilgrastim 8enzalutamide 8Trastuzumab 7Oxycodone 7Nivolumab 7Imiquimod 7Gemcitabine 7Epoetin Alfa 7icotinib 6Rituximab 6Prednisone 6Pemetrexed 6Oxaliplatin 6Leuprolide 6Fulvestrant 6Diclofenac 6Dexamethasone 6Cisplatin 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 4 × INDUSTRY × Denosumab × Clear all
NCT04586660 2025-10-01

Study of XGEVA® (Denosumab) in Chinese Adults and Skeletally Mature Adolescents With Giant Cell Tumor of the Bone

Amgen

Phase 4 Active not recruiting
36 enrolled

Giant Cell Tumor of Bone

NCT03301857 2024-05-20

Long-term Safety Follow-up of Subjects With Giant Cell Tumor of Bone Treated With Denosumab in Study 20062004

Amgen

Phase 4 Completed
85 enrolled 13 charts

Giant Cell Tumor of Bone

NCT02101164 2015-02-18

Evaluate Time Associated With the Preparation & Administration of Denosumab/Pamidronate in Patients With Solid Tumors and Metastatic Bone Disease

Amgen

Phase 4 Withdrawn

Bone Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡